Clinical trials: SARS-COV2
Covid-19
COVID-19 Convalescent Plasma for Mechanically Ventilated Population
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it can improve patients' health when they are sick with COVID-19.
- Trial name
- NCT04388527
- Testing
- COVID-19 Convalescent Plasma
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pennsylvania
COVID-19 (Healthy Volunteers)
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study were: To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
- Trial name
- NCT04537208
- Testing
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose)
- Where
- 11 sites in United States
- Volunteers
- 441 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
SARS-CoV-2, Covid19
Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada
In order to assess the mother-to-infant and potential vertical transmission of SARS-CoV-2 infection in pregnant women, maternal and neonatal biological samples were prospectively collected from women with confirmed or suspected…
- Conditions
- SARS-CoV-2, Covid19, Corona Virus Infection, Infectious Disease Transmission, Vertical
- Trial name
- COPE (NCT04913948)
- Testing
- No intervention
- Where
- 12 sites in Canada
- Volunteers
- 246 people
- Sponsor
- Ottawa Hospital Research Institute
COVID-19
A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or…
- Trial name
- NCT05067933
- Testing
- VXA-CoV2-1.1-S
- Where
- 4 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID-19
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with…
- Trial name
- NCT04333225
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Covid19
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
- Trial name
- NCT04707534
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Oklahoma
Coronavirus Disease 2019 (COVID-19)
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC)…
- Trial name
- NCT04409509
- Testing
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
- Where
- 14 sites in United States
- Volunteers
- 124 people
- Sponsor
- CSL Behring
COVID-19, Myocardial Injury
Myocardial Injury and Quality of Life After COVID-19
In this observational study follow-up and dynamic observation will be conducted on the participants recovered from pneumonia caused by COVID-19.
- Conditions
- COVID-19, Myocardial Injury, Myocarditis Post Infection
- Trial name
- NCT04794062
- Where
- Russia
- Volunteers
- 119 people
- Sponsor
- Voronezh Regional Clinical Consultative and Diagnostic Center
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
COVID-19
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
ACTT-2 will evaluate the combination of baricitinib and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized.
- Trial name
- NCT04401579
- Testing
- Remdesivir, Baricitinib
- Where
- 71 sites in United States, Denmark and 6 more
- Volunteers
- 1,033 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sars-CoV2, COVID
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than…
- Trial name
- NCT04401293
- Testing
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 257 people
- Sponsor
- Northwell Health
SARS-CoV-2 Infection
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19.
- Trial name
- NCT05263908
- Testing
- nirmatrelvir / ritonavir
- Where
- Japan
- Volunteers
- 3,346 people
- Sponsor
- Pfizer
Sars-CoV2, Serum; Disease
Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic
The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue.
- Trial name
- PRO-SERO-COV (NCT04426006)
- Testing
- PRO-SERO-COV
- Where
- France
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Institut Bergonié
COVID-19
Study of Open Label Losartan in COVID-19
This is an open label, phase 1 clinical trial to evaluate the safety of losartan in respiratory failure due to COVID-19. Briefly, 34 patients with COVID-19 and respiratory failure who meet eligibility criteria and agree to…
- Trial name
- NCT04335123
- Testing
- Losartan
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Kansas Medical Center
Covid19
Dräger COVID-19 Antigen Test Clinical Performance Study
The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2 detection in clinical nasal specimens.
- Trial name
- NCT04698993
- Testing
- Dräger Antigen Test SARS-CoV-2
- Where
- Germany
- Volunteers
- 388 people
- Sponsor
- Drägerwerk AG & Co. KGaA
Covid19
Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19
The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
- Trial name
- NCT04545008
- Testing
- Famotidine, N-Acetyl cysteine
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Prisma Health-Upstate
COVID-19
SARS-CoV-2/COVID-19 Prevalence Study
The COVID-19 Prevention Network (CoVPN) is doing a study to estimate the number of people who have or have had the SARS-CoV-2 virus in different communities in the United States.
- Trial name
- NCT04658121
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 26,211 people, healthy volunteers welcome
- Sponsor
- COVID-19 Prevention Network
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI US (NCT04380688)
- Testing
- Acalabrutinib
- Where
- 31 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
COVID-19
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis
- Trial name
- NCT04498273
- Testing
- Apixaban 2.5 MG, Apixaban 5MG, Aspirin
- Where
- 71 sites in United States
- Volunteers
- 657 people
- Sponsor
- Frank C Sciurba